Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » The Scan » Now, Developer

Now, Developer

Jan 13, 2020

23andMe has licensed an antibody it developed to treat inflammatory diseases to the Spanish drugmaker Almirall, according to Bloomberg. 

"This is a seminal moment for 23andMe," Emily Drabant Conley, the vice president of business development at 23andMe, tells Bloomberg. "We've now gone from database to discovery to developing a drug."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Not Up to the Promise

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

Quick!

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

Preconception Carrier Screening Trial Begins in Australia

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

PNAS Studies on Common LoF Genes, Testis Development Determinants, Coral Interactions

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.

What's Popular?

In Business News

  1. Guardant Health Prices $315M Public Offering

  2. 10x Genomics, Collaborators Develop Targeted Single-Cell Gene Expression Methods

    Premium

  3. Personalis, Sarepta Therapeutics Exploring Immune Response to Precision Genetic Therapeutics

  4. Seven Bridges Joins International Genomic Cancer Research Effort

  5. Agilent to Raise $500M Through Senior Notes Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.